Jump to content

TACT908

Add links
From Wikipedia, the free encyclopedia

TACT908
Clinical data
Other namesTACT-908; Compound 28-12; 2ZEDMA; [2-(Indolizin-1-yl)ethyl]dimethylamine; Indolizine-DMT
Drug classSerotonin receptor agonist; Serotonin 5-HT1B receptor agonist; Non-hallucinogenic serotonin 5-HT2A receptor agonist
Identifiers
  • 2-indolizin-1-yl-N,N-dimethylethanamine
PubChem CID
Chemical and physical data
FormulaC12H16N2
Molar mass188.274 g·mol−1
3D model (JSmol)
  • CN(C)CCC1=C2C=CC=CN2C=C1
  • InChI=1S/C12H16N2/c1-13(2)9-6-11-7-10-14-8-4-3-5-12(11)14/h3-5,7-8,10H,6,9H2,1-2H3
  • Key:CBZZXMYTGARRHB-UHFFFAOYSA-N

TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist which is under development for the treatment of cluster headaches.[1][2][3] It is an analogue and positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring.[1]

The drug acts as a serotonin 5-HT1B and 5-HT2A receptor agonist.[1][3] Its EC50Tooltip half-maximal effective concentration at the serotonin 5-HT2A receptor is 52 nM (EmaxTooltip maximal efficacy ≈ 30% of that of serotonin) and its EC50 at the serotonin 5-HT1B receptor is 143 nM.[1] TACT908 is said to be a non-hallucinogenic serotonin 5-HT2A receptor agonist.[1][3] It showed little or no activity at 45 other screened targets, including the serotonin 5-HT1A, 5-HT2B, and 5-HT3 receptors as well as the monoamine transporters (MATs).[1] Other serotonin receptors besides the preceding, such as the serotonin 5-HT2C receptor, were not assessed.[1] The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) (IC50Tooltip half-maximal inhibitory concentration = 7,252 nM).[1]

TACT908 is under development by Tactogen.[1][2][3] It was patented by Matthew Baggott and Tactogen in 2023.[1] As of January 2025, the drug is in preclinical research for cluster headaches.[2][3]

The α-methyl and N-desmethyl analogue of TACT908, 1ZP2MA ([1-(indolizin-1-yl)propan-2-yl](methyl)amine or 1-(indolizin-1-yl)-N-methylpropan-2-amine), has also been characterized and described.[1] It is the indolizine analogue of α,N-dimethyltryptamine (α,N-DMT or N-methyl-αMT).[1] 1ZP2MA was found to be a potent dopamine releasing agent, with an EC50 of 62 nM.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i j k l m WO patent 2023183613A2, Matthew J. Baggott, "Indolizine compounds for the treatment of mental disorders or inflammation", published 2023 September 28, assigned to Tactogen 
  2. ^ a b c Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  3. ^ a b c d e "Tactogen Inc – Pipeline". Tactogen Inc. Tactogen. 8 February 2021. Retrieved 29 January 2025. OUR PIPELINE: [...] COMPOUND: TACT908. TARGETS: 5-HT1B, 5-HT2A ***. INDICATION: Cluster Headache. Prevalence: 0.24%. STATUS: Preclinical. [...] ***Partial agonist at 2A, non-hallucinogenic.



Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://en.wiki.x.io/w/index.php?title=TACT908&oldid=1272835377"